Oppenheimer Defends Questcor (QCOR) on Acthar Concerns; Says Sell-Off Overdone
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Questcor Pharma (QCOR) to Hold Conf. Call Following 48% Dive on Acthar Concerns
September 20, 2012 7:16 AM EDTQuestcor Pharmacueticals, Inc. (Nasdaq: QCOR) shares are a little higher Thursday morning following a massive 48 percent drop on Wednesday. The reason was concern that Aetna was going to drop reimbursement for Acthar Gel.
Questcor said... More
Questcor (QCOR) Comments on Insurance Policy Bulletin; Does Not See Material Impact
September 19, 2012 2:37 PM EDTQuestcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today commented on information regarding an insurance policy bulletin issued with respect to the Company's primary product H.P. Acthar® Gel (repository corticotropin injection) ("Acthar").
The Company is continuing to review the Clinical Policy Bulletin related to Acthar... More
